stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Return on invested capital
Grifols, S.A.'s return on invested capital over the twelve months to 30 September 2026 was 4.76%, up 0.0 percentage points from fiscal 2025 (4.74%). Over the past ten years it has ranged from 0.00% (fiscal 2022) to 8.64% (fiscal 2015); the current reading is higher than 72% of that period. That is below the Drug Manufacturers General industry median of 6.26% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 4.74% | 0.50 |
| FY2024 | 4.24% | 1.52 |
| FY2023 | 2.72% | 0.02 |
| FY2022 | 2.70% | 2.70 |
| FY2022 | 0.00% | (2.51) |
| FY2021 | 2.51% | 2.51 |
| FY2021 | 0.00% | (4.73) |
| FY2020 | 4.73% | 4.73 |
| FY2020 | 0.00% | (6.10) |
| FY2019 | 6.10% | 6.10 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 29.6% |
| BMY Bristol Myers Squibb Company compare | 13.2% |
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| SNY Sanofi compare | 7.05% |
| OGN Organon & Co. compare | 6.26% |
| GRFS Grifols, S.A. | 4.76% |
| BIIB Biogen Inc. compare | 1.94% |
| NSRX Nasus Pharma Ltd. compare | 0.00% |
| AMRN Amarin Corporation PLC compare | −16.6% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement